A single jab can almost eliminate a particular type of cancer
In England, a generation of young women who received the HPV vaccine as schoolgirls has now passed through their early twenties without a single cervical cancer death — a silence in the mortality record that speaks louder than any statistic. Published in the Lancet, the findings mark the first time in recorded history that a five-year stretch produced zero cervical cancer deaths in women aged 20 to 24, a direct consequence of a vaccination program begun in 2008. It is a reminder that preventive medicine, when it reaches enough people, can quietly erase suffering that once seemed inevitable — and a warning that the same progress can just as quietly unravel when the will to sustain it falters.
- For the first time ever, an entire five-year period passed without a single cervical cancer death in English women aged 20 to 24 — a number that should have been 23.
- Around 200 lives have been saved since the HPV vaccination program launched in 2008, with vaccinated women now facing near-zero risk of dying from cervical cancer before age 30.
- The triumph is shadowed by a troubling retreat: vaccination rates in England have dropped to 76%, well below the 90% threshold the WHO says is needed to eliminate cervical cancer as a public health threat by 2040.
- Women like Alexandra Legg — born just before the vaccine arrived and diagnosed with cervical cancer at 30 — embody the cost of the gap, and now advocate fiercely so their own daughters will not face the same fate.
- The government is pushing community pharmacy rollouts and HPV self-testing kits, but researchers and cancer charities warn that targeted action in low-uptake communities is urgently needed to protect the progress already won.
In the five years between 2020 and 2024, not one woman aged 20 to 24 died of cervical cancer in England — a first in recorded history. Researchers estimate that without the HPV vaccine, roughly 23 deaths would have been expected in that window alone. The finding, published in the Lancet, traces the impact of England's vaccination program back to 2008, when schoolgirls were first offered the jab. In total, around 200 lives are estimated to have been saved since the program began. For those vaccinated at ages 12 or 13, the protection is near-absolute: their risk of dying from cervical cancer before 30 has fallen to almost nothing, compared to roughly 20 annual deaths in that age group before vaccination became routine.
Lead researcher Peter Sasieni of Queen Mary University of London described the result as almost difficult to comprehend — a single jab capable of nearly eliminating a type of cancer. HPV, the virus responsible for almost all cervical cancers, spreads through skin-to-skin contact and can quietly trigger abnormal cell changes years after infection. The vaccine stops that process before it starts. Since 2019, boys have also been offered the jab, extending protection against several other cancers and reducing transmission.
Yet the story carries a serious undercurrent. Cervical cancer still affects around 3,300 women in the UK each year, and vaccination rates have been slipping — falling to 76% in 2024-25, well below the 90% the WHO considers necessary to eliminate the disease as a public health threat. The UK government has pledged elimination by 2040, but the current trajectory runs counter to that ambition.
Alexandra Legg was born just before the vaccine reached England and missed the school program entirely. Diagnosed with cervical cancer at 30, while planning her wedding, she underwent surgery that removed lymph nodes but preserved part of her cervix. A year later, she gave birth to her daughter Ivy — whose middle name, Marvella, means miracle. Legg now advocates for the vaccine, determined her daughter will receive it the moment she is eligible.
Sasieni calls the lives saved so far merely the tip of the iceberg, expecting the impact to grow as vaccinated generations age. Cancer Research UK, which funded the study, is pressing the government for targeted outreach in communities where uptake remains lowest. Plans are underway to expand access through pharmacies and HPV self-testing kits — but whether these measures can reverse the slide remains the defining question for a program that has already proven what is possible.
In the five years between 2020 and 2024, not a single woman aged 20 to 24 died of cervical cancer in England. It was a milestone that had never occurred before—a full five-year stretch with zero deaths in that age group. Without the HPV vaccine, researchers estimate roughly 23 deaths would have been expected during that same window. Instead, the numbers simply stopped.
The finding comes from a study published in the Lancet, which tracked the impact of England's cervical cancer vaccination program that began in 2008, when schoolgirls were first offered the human papillomavirus jab. The analysis suggests that around 200 lives have been saved in England since the program's launch. For women vaccinated at ages 12 or 13, the protection is even more striking: they now face close to zero risk of dying from cervical cancer before turning 30. Before vaccination became routine, that age group saw roughly 20 deaths annually.
Peter Sasieni, the lead researcher at Queen Mary University of London, called the result almost difficult to comprehend. "It's incredible to think that a single jab can almost eliminate a particular type of cancer," he said. The virus behind nearly all cervical cancers—HPV, or human papillomavirus—spreads through close skin-to-skin contact. Most infections clear on their own, but some trigger abnormal cell changes that can develop into cancer years later. The vaccine interrupts that chain before it begins.
Yet the story is not one of uncomplicated triumph. Cervical cancer remains the 14th most common cancer among women in the UK, with roughly 3,300 new diagnoses each year. And vaccination rates have begun to slip. In 2024-25, only 76 percent of girls in England received the vaccine by age 15—well below the 90 percent threshold the World Health Organization says is necessary to eliminate cervical cancer as a public health threat. The UK government has pledged to reach that elimination goal by 2040, but current momentum is moving in the wrong direction.
Alexandra Legg was born just before the vaccine arrived in England. She missed the school program entirely. In 2021, at age 30, while planning her wedding, she was diagnosed with cervical cancer. "I remember hearing the words and I just couldn't really breathe very well," she recalls. Her treatment required removal of lymph nodes from her abdomen, though surgeons managed to preserve part of her cervix. A year later, she gave birth to her daughter, Ivy—whose middle name, Marvella, means miracle. "Those nine months were so scary because I was at such risk of losing her at any point," Legg says. She has become an advocate for the vaccine, determined that her daughter will receive it as soon as she is eligible.
Sasieni describes the reduction in deaths as merely "the tip of the iceberg." As vaccinated generations age, he expects the life-saving impact to grow substantially. The vaccine has also been offered to boys since 2019, protecting them against anal, penile, throat, and mouth cancers while reducing transmission to girls. Yet the challenge now is not scientific but practical: reaching the communities where uptake remains lowest. Michelle Mitchell, chief executive of Cancer Research UK, which funded the study, emphasized the urgency. "It's essential that the UK Government and health systems urgently address this with targeted action to reach communities where uptake is the lowest." The Department of Health and Social Care has announced plans to boost vaccination through community pharmacies and is sending HPV self-testing kits to women who have not attended screening. The question is whether these efforts will be enough to reverse the slide and keep the momentum that has already saved hundreds of lives.
Notable Quotes
It's incredible to think that a single jab can almost eliminate a particular type of cancer— Prof Peter Sasieni, Queen Mary University of London
I'm a real advocate for this vaccine and when Ivy is old enough, she'll be first in the queue— Alexandra Legg, cervical cancer survivor
The Hearth Conversation Another angle on the story
So we've gone from 20 deaths a year in young women to zero in a five-year stretch. That's not just progress—that's the disease being stopped before it starts.
Exactly. And the remarkable part is it happened because of a decision made in 2008 to vaccinate 12 and 13-year-olds. We're seeing the payoff now, nearly two decades later.
But the vaccination rates are dropping. Why would that happen when the evidence is this clear?
That's the harder question. It's not about the science anymore—it's about reaching people, about trust, about access. Seventy-six percent sounds high until you realize ninety percent is what you actually need.
And Alexandra Legg's story—she just missed the program by a few years.
Right. She was born just before it started. She got cervical cancer at 30, went through surgery, and then had a pregnancy that could have ended in tragedy. Now she's an advocate for the vaccine. There's something almost cruel about that timing.
What does Sasieni mean when he calls this the tip of the iceberg?
The vaccinated cohorts are still young. As they age into their 30s, 40s, 50s, we'll see the full protective effect. The deaths prevented now are just the beginning of what's coming.
So the real work now is getting the vaccination rate back up.
Yes. The science has done its job. Now it's about policy, community outreach, removing barriers. The UK government has set 2040 as the year to eliminate cervical cancer as a public health problem. But if vaccination rates keep falling, that becomes much harder.